ArkBio Overview

  • Founded
  • 2013

Founded
  • Status
  • Private

  • Employees
  • 71

Employees
  • Latest Deal Type
  • IPO

  • (Announced)
  • Investors
  • 24

ArkBio General Information

Description

Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis. The company's leading drug AK0529 specifically inhibits RSV (Respiratory Syncytial Virus) replication by blocking viral entry and syncytial formation, providing an effective first-line antiviral therapy for RSV infection in infants and the elderly.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • No. 25
  • Lane 388, Shengrong Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021 0000 0000

ArkBio Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ArkBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. IPO 06-Jul-2021 00000 Announced Clinical Trials - Phase 3
9. Later Stage VC (Series C1) 01-Jan-2021 0000 00000 00000 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series C) 01-Dec-2020 0000 00000 00000 Completed Clinical Trials - Phase 3
7. Secondary Transaction - Private 18-Nov-2020 000.00 000.00 Completed Clinical Trials - Phase 3
6. Later Stage VC 13-Oct-2020 000.00 000.00 00000 Completed Clinical Trials - Phase 2
5. Early Stage VC (Series B) 01-Jun-2018 0000 000.00 00000 Completed Clinical Trials - Phase 2
4. Early Stage VC (Series A1) 06-Feb-2017 000 000.00 0000 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 08-Apr-2015 00.00 00.00 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 01-Dec-2014 $2.2M $4.2M 000.00 Completed Startup
1. Seed Round 10-Dec-2013 $2M $2M 000.00 Completed Startup
To view ArkBio’s complete valuation and funding history, request access »

ArkBio Executive Team (5)

Name Title Board Seat Contact Info
Zheng Wu Ph.D Chief Executive Officer & Chairman & Founder
Haiqing Yuan Ph.D Chief Scientific Officer & Chief Operating Officer
Yan Wu MD Chief Medical Officer
Gianni Gromo Ph.D Scientific Advisor
You’re viewing 4 of 5 executive team members. Get the full list »

ArkBio Board Members (2)

Name Representing Role Since
Xubo Hu Qiming Venture Partners Board Member 000 0000
Zheng Wu Ph.D ArkBio Chief Executive Officer & Chairman & Founder 000 0000
To view ArkBio’s complete board members history, request access »

ArkBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ArkBio Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CITIC Securities Investment Bank Minority 000 0000 000000 0
Daoyuan Capital Venture Capital Minority 000 0000 000000 0
DT Capital Partners Venture Capital Minority 000 0000 000000 0
DYEE Capital Venture Capital Minority 000 0000 000000 0
Hillhouse Capital Group PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 24 investors. Get the full list »